Return to site

A World Premiere in Parkinson’s Disease

With significant clinical results published in the Nature Medicine Journal, InBrain Pharma is about to durably modify the advanced Parkinson’s disease management

A breakthrough therapeutic approach for Parkinson’s disease:
Anaerobic dopamine brain infusion

Lille, January 27, 2024 – InBrain Pharma, a clinical stage biotech specialized in therapeutic solution development against neurodegenerative diseases , is thrilled to announce the publication of the outstanding results of the Phase I/II DIVE-I monocentric study conducted at the Lille University Hospital in the Nature Medicine Journal. More information